Anti-inflammatory effects of *Perilla frutescens* in activated human neutrophils through two independent pathways: Src family kinases and Calcium

Chun-Yu Chen1,2,3, Yann-Lii Leu2, Yu Fang1, Chwan-Fwu Lin4, Liang-Mou Kuo2,5, Wei-Che Sung1, Yung-Fong Tsai1,2,3, Pei-Jen Chung1, Ming-Chung Lee6, Yu-Ting Kuo1, Hsuan-Wu Yang1 & Tsong-Long Hwang1,7,8

The leaves of *Perilla frutescens* (L.) Britt. have been traditionally used as an herbal medicine in East Asian countries to treat a variety diseases. In this present study, we investigated the inhibitory effects of *P. frutescens* extract (PFE) on N-formyl-Met-Leu-Phe (fMLF)-stimulated human neutrophils and the underlying mechanisms. PFE (1, 3, and 10 μg/ml) inhibited superoxide anion production, elastase release, reactive oxygen species formation, CD11b expression, and cell migration in fMLF-activated human neutrophils in dose-dependent manners. PFE inhibited fMLF-induced phosphorylation of the Src family kinases (SFKs), Src (Tyr416) and Lyn (Tyr396), and reduced their enzymatic activities. Both PFE and PP2 (a selective inhibitor of SFKs) reduced the phosphorylation of Burton’s tyrosine kinases (Tyr223) and Vav (Tyr174) in fMLF-activated human neutrophils. Additionally, PFE decreased intracellular Ca2+ levels ([Ca2+]i), whereas PP2 prolonged the time required for [Ca2+]i to return to its basal level. Our findings indicated that PFE effectively regulated the inflammatory activities of fMLF-activated human neutrophils. The anti-inflammatory effects of PFE on activated human neutrophils were mediated through two independent signaling pathways involving SFKs (Src and Lyn) and mobilization of intracellular Ca2+.

*Perilla frutescens* (L.) belongs to the Lamiaceae family and is widely used as a common vegetable crop, condiment, and traditional herbal medicine in East Asian countries1,2. In traditional medicine, the leaves of *P. frutescens* are utilized to treat various illnesses such as cough, respiratory tract infection, food poisoning, diarrhea, and premature delivery3,4. The compounds contained in *P. frutescens* have attracted interest for their biological activities, which include anti-inflammatory5,6, anti-oxidative7,8, anti-HIV9,10, anti-tumor11, and anti-microbial functions12. Studies also indicated that *P. frutescens* can decrease inflammatory responses in immune cells, such as macrophages13,14 and mast cells6,15. However, the biological effects of *P. frutescens* on human neutrophils and the molecular mechanisms underlying these remain poorly understood.

Neutrophils are the most plentiful leukocyte in human blood, accounting for about 50-75% of circulating leukocytes. During inflammation, they are the first immune cells to arrive and execute their pathogen-eliminating function via multiple intra- and extracellular mechanisms16-18. However, the reactive oxygen species (ROS) and...
Lytic enzymes can also damage healthy surrounding tissue, resulting in deleterious inflammatory diseases, such as acute lung injury, chronic obstructive pulmonary disease, and asthma\textsuperscript{19–22}. In order to ameliorate these conditions, many studies have investigated the pharmacological modulation of activated human neutrophils by natural products and their mechanisms of action.

This present study investigated the modulatory effects of a \textit{P. frutescens} var. \textit{crispa} extract (PFE) in activated human neutrophils. We found that a non-toxic level of PFE reduced superoxide anion (O$_2^-$) production, elastase release, ROS formation, CD11b expression, and chemotactic migration in N-formyl-Met-Leu-Phe (fMLF)-induced human neutrophils.

**Results**

**PFE inhibited O$_2^-$ production, elastase release, and ROS formation in fMLF-activated human neutrophils.** Human neutrophils ($6 \times 10^5$ cells/ml) were pre-incubated with dimethylsulfoxide (DMSO) or PFE (1, 3, and 10 $\mu$g/ml) and then activated with fMLF (0.1 $\mu$M). (A, B) O$_2^-$ and elastase release were detected spectrophotometrically using cytochrome c reduction and elastase substrate, respectively. (C) The fluorescence intensity of dihydrodorhodamine 123 (DHR123) was used to detect the intracellular ROS. The ROS formation in fMLF-activated neutrophils pretreated with PFE (red line) was decreased, as compared with those without PFE (black line). The dashed line indicated neutrophils that were not treated with fMLF (basal group). (D) The mean values of fluorescence intensity from panel C. Data are expressed as the mean $\pm$ standard error of the mean, n = 7, *$p < 0.05$, **$p < 0.001$, as compared to the fMLF group.
Neutrophils was also inhibited by PFE, with an IC$_{50}$ value of 1.93 ± 0.24 μg/ml (Fig. 1C,D). PFE (10 μg/ml) did not affect basal O$_{2}$$^-•$ production or elastase release in unstimulated neutrophils (Fig. 1A,B). Furthermore, our experiments showed that PFE (10 μg/ml) did not promote lactate dehydrogenase (LDH) release (data not shown), suggesting that PFE did not exert cytotoxic effects in human neutrophils.

**PFE inhibited CD11b expression and cell migration in fMLF-activated human neutrophils.** CD11b/CD18 is involved in cellular adhesion between activated neutrophils and endothelial cells. When neutrophils are stimulated, they rapidly immobilize through activation of integrin CD11b/CD18, and subsequent modulation of this attachment allows migration. Our results demonstrated that fMLF stimulation of human neutrophils resulted in significant up-regulation of CD11b expression, while PFE (1, 3, and 10 μg/ml) inhibited CD11b expression in fMLF-activated human neutrophils with an IC$_{50}$ value of 4.49 ± 1.39 μg/ml (Fig. 2A,B). Furthermore, fMLF-induced neutrophil migration was reduced in the presence of PFE (3 and 10 μg/ml; Fig. 2C). The IC$_{50}$ for this effect was 5.36 ± 1.06 μg/ml.

**PFE inhibited the activation of SFKs.** SFKs are protein-tyrosine kinases that play important roles in neutrophil activation triggered by the chemotactic peptide, fMLF$^{24}$. Our immunoblotting analyses demonstrated that fMLF stimulated the phosphorylation of SFKs (Tyr416), Src (Tyr416), and Lyn (Tyr 396) in human neutrophils; PFE attenuated phosphorylation of these proteins (Fig. 3A). PP2, a selective inhibitor of SFKs, also inhibited phosphorylation of these SFKs (Fig. 3B). In addition, we investigated whether PFE inhibited the enzymatic activities of Src and Lyn. The results of this analysis indicated that PFE inhibited Src and Lyn tyrosine kinase activities in a concentration-dependent manner (IC$_{50}$ = 5.21 ± 0.36 μg/ml and 2.51 ± 0.29, respectively) (Fig. 4A,B). PP2 was used as a positive control.
PFE attenuated the phosphorylation of Burton’s tyrosine kinases (Btk).

Btk belongs to the Tec family of tyrosine kinases, which includes Itk, Tec, Txk, and Bmx. Btk is involved in G-protein coupled receptor (GPCR) signal transduction. Immunoblotting for phospho-Btk demonstrated that both PFE (3 and 10 μg/ml) and PP2 (1 μM) attenuated the phosphorylation of Btk Tyr223 (Fig. 5A,B). Furthermore, we used a Btk inhibitor, LFM-A13, to explore the role of Btk in the regulation of neutrophil activation. Figure 5C,D revealed that LFM-A13 (1, 3, and 10 μM) decreased O2•− and elastase release from activated human neutrophils, with an IC50 of 2.50 ± 0.21 μM and 5.85 ± 1.36 μM, respectively.

Figure 3. *P. frutescens* extract (PFE) inhibited the phosphorylation of Src family kinases (SFKs) in *N*-formyl-Met-Leu-Phe (fMLF)-activated human neutrophils. Human neutrophils were pre-incubated with dimethylsulfoxide (DMSO). (A) PFE (3 and 10 μg/ml), or (B) PP2 (SFK inhibitor, 1 μM) before stimulation with fMLF (0.1 μM). All the Western blotting experiments were performed under the same condition. After transferring the blots onto nitrocellulose membranes, we immediately cropped the targeted blots according to referenced indicating markers, and then targeted proteins were immunoblotted with its specific monoclonal antibody. (A,B) Representative images from one of four independent experiments of Western blotting using anti-phospho antibodies directed against SFKs, Src, and Lyn were shown. Bands on the blots were analyzed using a densitometer, and the quantitative ratios for all samples were normalized to the corresponding total protein or to glyceraldehyde 3-phosphate dehydrogenase (GAPDH).

Figure 4. *P. frutescens* extract (PFE) inhibited Src and Lyn enzymatic activity. (A) Src (3 ng/ml) or (B) Lyn (3 ng/ml) was incubated with dimethylsulfoxide (DMSO, as control), PFE (3, 10, and 30 μg/ml), or PP2 (3 μM) for 10 min, and then ATP/substrate was added to the reaction mixture for 60 min prior to measurement of Src or Lyn activity, as described in the Methods section. Data are expressed as the mean ± standard error of the mean, n = 3, **p < 0.001, as compared to the control group.
PFE reduced the phosphorylation of Vav. As a member of the guanine nucleotide exchange factors (GEFs) family, Vav activates Rac activity by replacing the GDP in its switch protein with GTP, leading to the activation of NADPH oxidase. Previous studies showed that SFKs induced Vav phosphorylation and activation. Therefore, we explored whether Vav was involved in PFE-caused inhibition. Immunoblotting analyses revealed that PFE (3 and 10 μg/ml), PP2 (1 μM), and LFM-A13 (10 μM) inhibited the phosphorylation of Vav Tyr174 in fMLF-activated neutrophils (Fig. 6).

PFE, but not PP2, decreased intracellular Ca^{2+} mobilization. Ca^{2+} is an important second messenger in human neutrophil activations. Stimulation of neutrophils with fMLF elicited a rapid increase of the intracellular Ca^{2+} concentration ([Ca^{2+}]_{i}). Our results demonstrated that PFE (10 μg/ml) diminished the amplitude of this increase (Fig. 7A); while PP2 (1 μM) increased the time required for [Ca^{2+}]_{i} to return to half of its peak value (t_{1/2}, Fig. 7B). Moreover, we found that BAPTA/AM (1–20 μM), a membrane permeable Ca^{2+} chelator, reduced O_{2}^{-} and elastase release from neutrophils activated by fMLF (Fig. 7C,D).

Fingerprint chromatogram of PFE. The fingerprint chromatogram of PFE was obtained by high performance liquid chromatography (HPLC) for quality control. The detector wavelength at 210 nm showed superior separation compared with other wavelengths. Identification of PFE was dependent on retention time and UV spectra in comparison with the standard. The fingerprint chromatogram showed peaks of rosmarinic acid, oleanolic acid, and linoleic acid eluted at 32.5, 72.1, and 73.4 min, respectively (Fig. 8).

Discussion
P. frutescens is a popular vegetable and food condiment that also commonly utilized as an herbal medicine in many Asian countries. Previous studies demonstrated that P. frutescens has important anti-inflammatory effects. Nevertheless, little is known about the pharmacological mechanisms underlying these effects in human neutrophils. In the present study, we found that PFE inhibited the respiratory burst, degranulation, and chemotactic migration of fMLF-activated human neutrophils through inhibiting SFKs (Src and Lyn) pathway and intracellular Ca^{2+} mobilization.

Many studies have revealed that compounds found in P. frutescens have anti-oxidative effects. In this study, we found that PFE reduced O_{2}^{-} production and ROS formation in fMLF-induced human neutrophils. We also used a cell-free xanthine/xanthine oxidase system and found that higher concentration of PFE (10 μg/ml and 30 μg/ml)
had direct $\text{O}_2^\cdot -$ scavenging activity ($\text{IC}_{50} = 23.43 \pm 0.34 \mu g/ml$; data not shown); this finding was consistent with a previous report\textsuperscript{7}. These findings suggested that PFE reduced ROS levels, either by modulating cellular signaling or by direct free radical scavenging activity.

SFKs are non-receptor tyrosine kinases that regulate cell growth, differentiation and activation via various intracellular signaling pathways. Several SFKs such as Lyn, Hck and Fgr are expressed in human neutrophils\textsuperscript{34,35}. These kinases are involved in fMLF-activated signal transduction processes\textsuperscript{24,36-38}. In our studies, a selective inhibitor of SFKs (PP2) significantly reduced $\text{O}_2^\cdot -$ production and elastase release in neutrophils stimulated with fMLF. CD11b expression and chemotactic migration of fMLF-induced neutrophils were also reduced in the presence of PP2 (data not shown). Other studies\textsuperscript{24} and our data support the role of SFKs in signal transduction triggered by fMLF receptors and neutrophil activation. Furthermore, we demonstrated that PFE inhibited the phosphorylation of the SFKs, Src, and Lyn in fMLF-activated neutrophils. Furthermore, we found that PFE directly inhibited the enzymatic activities of Src and Lyn. These data suggested that PFE influenced the activities of SFKs, which plays an important role in the functional responses to fMLF.

Btk belongs to the Tec family of tyrosine kinases. Previous reports have revealed a tight relationship between SFKs and the Tec family\textsuperscript{27,29,39}. The phosphorylation of Btk at Tyr551 and subsequent autophosphorylation at Tyr223, which is necessary for its full activation, are closely correlated with the activity of SFKs\textsuperscript{40,41}. In the present study, we found that an inhibitor of Btk (LFM-A13) reduced $\text{O}_2^\cdot -$ production and elastase release in fMLF-activated human neutrophils, which was consistent with a previous study\textsuperscript{29} describing the role of Btk in neutrophil activation. Moreover, we observed that the phosphorylation of Btk was significantly inhibited by PP2, suggesting that Btk was downstream of SFKs. In addition, Vav acts as a GEF for Rac, which is a subfamily of the RHO family, leading

**Figure 6.** *P. frutescens* extract (PFE), PP2, and LFM-A13 attenuated the phosphorylation of Vav in N-formyl-Met-Leu-Phe (fMLF)-activated human neutrophils. Human neutrophils were incubated with dimethylsulfoxide (DMSO), (A) PFE (3 and 10 $\mu g/ml$), (B) PP2 (1 $\mu M$), or (C) LFM-A13 (10 $\mu M$) before stimulation with fMLF (0.1 $\mu M$). Phosphorylated Vav and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were detected by immunoblotting. Representative images from one of four independent experiments are shown.
to the activation of NADPH oxidase24,30–32. Fumagalli et al. demonstrated that SFKs phosphorylated Vav in the signaling pathway triggered by fMLF, resulting in neutrophil activation24. Our immunoblotting data showed that both PP2 and LFM-A13 inhibited the phosphorylation of Vav (Fig. 5C), suggesting that SFKs and Btk modulated Vav activation. In agreement with this finding, PFE significantly inhibited the fMLF-induced phosphorylation of Btk and Vav in human neutrophils. Taken together, the results of this study provided evidence for the role of SFKs/Btk/Vav in human neutrophil activation triggered by fMLF, and indicated that PFE regulated human neutrophil activation by inhibiting this SFKs/Btk/Vav signaling pathway.

Figure 7. *P. frutescens* extract (PFE), but not PP2, reduced intracellular Ca2+ mobilization in N-formyl-Met-Leu-Phe (fMLF)-activated human neutrophils. Fluo-3/AM-labeled human neutrophils were incubated with (A) PFE (10 μg/ml) or (B) PP2 (1 μM) for 5 min before stimulation of fMLF (0.1 μM). Fluorescence was monitored in a spectrofluorometer (n = 3). (C) O2˙− production and (D) elastase release were measured spectrophotometrically in fMLF-activated neutrophils incubated with dimethylsulfoxide (DMSO) or 1, 2-bis(o-aminophenoxy)ethane-N,N',N' N'-tetraacetic acid tetrasodium salt (BAPTA-AM; 1-20 μM) and then activated with fMLF/cytochalasin B (CB). Data are expressed as the mean ± standard error of the mean, n = 4, *p < 0.05, **p < 0.01, ***p < 0.001, as compared to the fMLF group.

Figure 8. Chromatography analysis of *P. frutescens* extract (PFE). The concentration of PFE for HPLC analysis was 4 mg/ml. The injection volume was 20 μl, and the UV detection wavelength was set at 210 nm. The HPLC fingerprint showed peaks of rosmarinic acid (RA), oleanolic acid (OA), and linoleic acid (LA) at 32.5, 72.1, and 73.4 min, respectively.
Ca²⁺ is a vital intracellular second messenger that contributes to neutrophil activation.⁴²,⁴³ The binding of fMLF to GPCR triggers a rapid and transient increase in [Ca²⁺]ᵢ, resulting in neutrophil activation. Some specific inhibitors of Ca²⁺ signaling have been investigated as anti-inflammatory drugs because of their suppressive effects on neutrophil functions⁴⁴. Our experiments using a Ca²⁺ chelator (BAPTA-AM) proved that increased [Ca²⁺]ᵢ was required for the fMLF-induced respiratory burst and elastase release. Furthermore, our study showed that PFE reduced the fMLF-induced amplification of [Ca²⁺]ᵢ. However, PP2 prolonged the time required for [Ca²⁺]ᵢ to resume its original equilibrium concentration. These findings inferred that the Ca²⁺ mobilization inhibited by PFE was independent of SFKs. Intracellular Ca²⁺ transients and SFKs are both important signal transduction pathways in fMLF-induced neutrophils.²³ Obviously, additional work is required to define the signal events linking SFKs and Ca²⁺ mobilization in human neutrophils.

Based on these findings, we conclude that PFE significantly inhibited fMLF-induced human neutrophil activation, including O₂⁻ production, elastase release, ROS formation, CD11b expression, and chemotactic migration. PFE inhibited activation of SFKs and Ca²⁺ mobilization, which represent two signaling pathways involved in fMLF-induced neutrophil activation (Fig. 9). Because the PFE used in the present study was a crude extract of *P. frutescens*, any of the chemical components of PFE may be involved in the effects and mechanisms described above. Further studies aimed at clarifying whether these two signaling pathways are regulated by one or more of the different chemical constituents of PFE should contribute to the development of more effective therapeutic options.

**Methods**

**Preparation of *P. frutescens* extract.** PFE was prepared by our co-author, Dr. Leu. *P. frutescens* (L.) Britt leaf powder was purchased from the Sun-Ten Pharmaceutical Co., Ltd. (Taipei, Taiwan). This contained the *P. frutescens* extract (67%) and corn starch (33%). The powder (1 g) was suspended in 10 ml ethanol at 37 °C for 4 h and then centrifuged at 5000 g for 20 min. The supernatant was filtered and lyophilized. The resulting PFE extract (PFE) was prepared by our co-author, Dr. Leu. Our study protocol was investigated and approved by the Institutional Review Board at Chang Gung Memorial Hospital, and written informed consent was obtained from every volunteer. The methods were carried out in accordance with the approved guidelines. Blood was drawn from healthy volunteers (aged 20–30 years) who had no congenital or systemic disease and did not take any medicine during the week prior to sample collection. Human neutrophils were isolated using a standard method of dextran sedimentation and centrifugation in a Ficoll-Hypaque gradient and hypotonic lysis of red blood cells.⁴⁵ The granulocyte layer was harvested and resuspended in Ca²⁺-free Hank's balanced salt solution (HBSS) at pH 7.4, and maintained at 8 °C until use. The voucher specimen (CGU-NP-PFE-327) was secured at the Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

**Reagents.** Dihydorhodamine 123 (DHR123) and fluo-3 acetoxymethoxyester (fluo-3/AM) were obtained from Molecular Probes (Eugene, OR, USA). 1, 2-Bis(o-aminophenoxy)ethene-N,N,N′,N′-tetracetic acid tetrakis-acetoxymethyl ester (BAPTA-AM) was from Tocris Bioscience (Ellisville, MO, USA). Antibodies directed against phosphorylated SFKs (Tyr416), Lyn, and phosphorylated Btk (Tyr223) were purchased from CellSignaling (Beverly, MA, USA). An antibody against phospho-Src (Tyr416) was purchased from Millipore (Billerica, MA, USA). Antibodies against phospho-Lyn (Tyr396), phospho-Vav (Tyr174), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were purchased from EnoGene (NY, USA). An antibody against Src was purchased from Epitomic (Burlingame, CA, USA). FITC-labeled anti-human CD11b was purchased from eBioscience (San Diego, CA, USA). Src and Lyn kinase enzyme systems were purchased from Promega (Madison, WI, USA). The MoXi Z automatic cell counter was purchased from ORFLO (Hailey, ID, USA). All other reagents were purchased from Sigma–Aldrich (St. Louis, MO, USA).

**Isolation of human neutrophils.** This study protocol was investigated and approved by the Institutional Review Board at Chang Gung Memorial Hospital, and written informed consent was obtained from every volunteer. The methods were carried out in accordance with the approved guidelines. Blood was drawn from healthy volunteers (aged 20–30 years) who had no congenital or systemic disease and did not take any medicine during the week prior to sample collection. Human neutrophils were isolated using a standard method of dextran sedimentation prior to centrifugation in a Ficoll-Hypaque gradient and hypotonic lysis of red blood cells.⁴⁵ The granulocyte layer was harvested and resuspended in Ca²⁺-free Hank's balanced salt solution (HBSS) at pH 7.4, and maintained at 8 °C until use. The voucher specimen (CGU-NP-PFE-327) was secured at the Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
4 °C until use. Greater than 98% cell viability was confirmed by trypan blue exclusion. The data presented for each specific experiment were derived from 4 to 7 samples.

**Measurement of O$_2^{-}$ production.** The reduction of ferricytochrome c was used to measure O$_2^{-}$ release from human neutrophils. Neutrophils (6 × 10$^5$ cells/ml) were incubated with 0.5 μg/ml ferricytochrome c and 1 mM CaCl$_2$ at 37 °C, and then treated with DMSO (as control), PFE, 4-amino-5-(4-chlorophenyl)-7-(4-butyl)pyrazolo[3,4-d]pyrimidine (PP2, a selective inhibitor of SFKs), or 2-cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide (LFM-A13, a Btk inhibitor), or BAPTA-AM (a Ca$^{2+}$ chelator) for 5 min. Neutrophils were activated by adding fMLF (0.1 μM) with cytochalasin B (1 μg/ml) pretreatment (fMLF/CB). The change in absorbance at 550 nm reflected the reduction of ferricytochrome c and was monitored continuously using a spectrophotometer (U-3010; Hitachi, Tokyo, Japan). O$_2^{-}$ release was calculated as described previously.

**Assessment of elastase release.** Human neutrophils (6 × 10$^5$ cells/ml) were equilibrated with an elastase substrate (MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide, 100 μM) at 37 °C for 2 min and then incubated with DMSO, PFE, PP2, LFM-A13, or BAPTA/AM for 5 min. Cells were activated by fMLF (0.1 μM)/CB (0.5 μg/ml) for a further 10 min. Elastase release was determined by measuring the changes in absorbance at 405 nm using a spectrophotometer (U-3010; Hitachi, Tokyo, Japan). The results were expressed as a percentage of the elastase release in the fMLF/CB-activated, drug-free, control group.

**Determination of ROS formation.** Cell-permeable DHR123, which is not fluorescent until oxidized, was used to detect intracellular ROS. Human neutrophils (1 × 10$^6$ cells/ml) were incubated in HBSS containing DHR123 (2 μM) for 10 min at 37 °C. They were then treated with PFE or PP2 for 5 min, and then activated by fMLF (0.1 μM)/CB (0.5 μg/ml) for 15 min. The change in fluorescence was analyzed by flow cytometry (FACSCalibur™; BD Bioscience, San Jose, CA, USA).

**Evaluation of LDH release.** LDH release was used as an indicator of cell membrane integrity and served as a general means to assess cytotoxicity. We used commercially available reagents (Promega) to determine the LDH level. Human neutrophils were treated with PFE (10 μM) for 60 min. LDH assay reagents was then added to the supernatant. LDH release was expressed as a percentage of the amount of enzyme liberated following incubation of human neutrophils with 0.1% Triton X-100 for 30 min at 37 °C.

**Measurement of CD11b expression.** CD11b/CD18 is a heterodimeric glycoprotein that is expressed on the plasma membrane of neutrophils. Neutrophils (5 × 10$^5$ cells/ml) were preincubated with PFE, PP2, or LMF-A13 for 5 min and then activated by fMLF (0.1 μM)/CB (0.5 μg/ml) for a further 5 min. The reaction was stopped by placing the cells on ice prior to centrifugation at 4 °C. The supernatant was discarded and the cells were resuspended in 0.5% bovine serum albumin for staining using a FITC-labeled-anti-CD11b antibody (1 μg) for 90 min at 4 °C. The fluorescence intensity of FITC-labeled anti-CD11b was then monitored using flow cytometry.

**Chemotactic migration assay.** Human neutrophil chemotactic migration was assessed using a microchemotaxis chamber with a 3-μm filter (Millipore). Neutrophils (5 × 10$^5$ cells/ml) were incubated with DMSO or PFE (3 and 10 μg/ml) for 5 min at 37 °C and then placed into the top chamber. HBSS containing fMLF (0.1 μM) was added to the bottom chamber. After incubation in a 5% CO$_2$ incubator for 60 min, the number of cells that migrated was determined by a MoxiZ automatic cell counter (ORFLO).

**Immunoblotting.** The neutrophils were treated with DMSO, PFE (3 and 10 μg/ml), PP2 (1 μM), or LMF-A13 (10 μM) for 5 min before stimulation with or without fMLF (0.1 μM) for another 30 sec at 37 °C. Cells were lysed in a buffer containing 50 mM HEPES (pH 7.4), 100 mM NaCl, 1 mM EDTA, 2 mM Na$_2$VO$_4$, 10 mM p-nitrophenyl phosphate, 5% β-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, 1% protease inhibitor cocktail (Sigma-Aldrich), and 1% Triton X-100. After brief sonication, the samples were centrifuged at 14,000 rpm for 20 min at 4 °C to yield whole-cell lysates. The proteins were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to membranes. After being blocked with 5% nonfat milk in a mixture of Tris-buffered saline and Tween 20 (TBS-T), the membranes were incubated with diluted primary antibodies at 4 °C overnight; these were anti-phospho-Src family (Tyr416), anti-phospho-Src (Tyr416), anti-Src, anti-phospho-Lyn (Tyr396), anti-Lyn, anti-phospho-Btk (Tyr223), anti-phospho-Vav (Tyr174), and anti-GAPDH antibodies. The membranes were washed with 0.05% TBS-T and incubated with diluted horseradish peroxidase-conjugated secondary antibodies at room temperature for 1 h. After being washed, enhanced chemiluminescence solution was added to the membranes and protein bands were detected using the BioSpectrum Imaging System (UVP; Upland, CA, USA).

**Src and Lyn kinase activity.** Src and Lyn kinase activity were determined by the ADP-Glo™ kinase assay kit (Promega) according to the manufacturer's instructions. Briefly, Src or Lyn kinase reactions were performed using a buffer containing Src or Lyn kinase, Src or Lyn kinase substrate, ATP (50 μM), and PFE (3, 10, and 30 μg/ml) or PP2 (3 μM) for 60 min. ADP-GloTM reagent was added to terminate the kinase reaction and deplete the remaining ATP. The luciferase/luciferin luminescence was recorded with a microplate reader (Infinite 200 Pro; Tecan, Männedorf, Switzerland).

**Examination of [Ca$^{2+}$]).** Human neutrophils (6 × 10$^5$ cells/ml) were incubated with Fura-3/AM (2 μM) at 37 °C for 30 min, followed by centrifugation and resuspension in HBSS solution containing CaCl$_2$ (1 mM). The Fura-3/AM-labeled neutrophils were treated with PFE (10 μg/ml) or PP2 (1 μM) for 5 min. The [Ca$^{2+}$], in response to fMLF (0.1 μM) was measured under continuous stirring using a spectrophotometer with an excitation wave
length of 488 nm and an emission wavelength of 520 nm. Maximum and minimum fluorescence values were obtained by adding 0.05% Triton X-100 and 20 mM ethylene glycol tetraacetic acid (EGTA) sequentially at the end of each experiment.

**Fingerprint chromatogram of PFE.** The HPLC analysis of PFE was conducted on a Waters HPLC system. The concentration of PFE was 4 mg/ml. The separation was performed using a reverse-phase column (Cosmosil 5C18-MS-II, 5 μm, 4.6 mm × 250 mm I.D.) connected with a guard column (Lichrospher RP-18 end-capped, 5 μm, 4.0 mm × 10 mm I.D.). The elution flow rate was 1.0 ml/min with a mobile phase gradient of A-B (A = 0.085% H₃PO₄, B = CH₃CN), which was varied as follows: 0–10 min, 90–85% A, 10–15% B; 10–20 min, 85–80% A, 15–20% B; 20–30 min, 80–60% A, 20–40% B; 30–55 min, 60–35% A, 40–55% B; 55–65 min, 35–0% A, 65–100% B; 65–80 min, 0–90% A, 100–10% B. The injection volume was 20 μl, and the UV detection wavelength was set at 210 nm.

**Statistical analysis.** Results were expressed as mean ± standard error of the mean (SEM). Computation of the 50% inhibitory concentration (IC₅₀) was computer-assisted (PHARM/PCS v.4.2). Statistical comparisons were made between groups using Student's t-test. Values of p less than 0.05 were considered to be statistically significant.

**References**

1. Urushima, H. et al. Perilla frutescens extract ameliorates DSS-induced colitis by suppressing proinflammatory cytokines and inducing anti-inflammatory cytokines. *Am J Physiol Gastrointest Liver Physiol* **308**, G32–41 (2015).
2. Jean, I. H. et al. Anti-inflammatory and antipruritic effects of luteolin from *Perilla* (frutescens L.) leaves. *Molecules* **19**, 6941–6951 (2014).
3. Makino, T. et al. Anti-inflammatory activity of *Perilla frutescens* and its active constituents. *Phytother Res* **17**, 240–243 (2003).
4. Wang, J., Tao, S., Xing, Y. & Zhu, Z. [Pharmacological effects of seu and baiyou]. *Zhongguo Zhong Yao Za Zhi* **22**, 48–51, 63 (1997).
5. Park, Y. D., Jin, C. H., Choi, D. S., Byun, M. W. & Jeong, Y. I. Biological evaluation of isoeugomaketone isolated from *Perilla frutescens* and its synthetic derivatives as anti-inflammatory agents. *Arch Pharm Res* **34**, 1277–1282 (2011).
6. Muller-Waldeck, E., Sitzmann, J., Schnitzler, W. H. & Grassmann, J. Determination of toxic perilla ketone, secondary plant metabolites and antioxidative capacity in five *Perilla frutescens* L. varieties. *Food Chem Toxicol* **48**, 264–270 (2010).
7. Saita, E. et al. Antioxidant activities of *Perilla frutescens* against low-density lipoprotein oxidation in vitro and in human subjects. *J Oleo Sci* **61**, 113–120 (2012).
8. Jun, H. I., Kim, B. T., Song, G. S. & Kim, Y. S. Structural characterization of phenolic antioxidants from purple perilla (*Perilla frutescens* var. acuta) leaves. *Food chemistry* **148**, 367–372 (2014).
9. Yamasaki, K. et al. Anti-HIV-1 activity of herbs in Labiatae. *Biol Pharm Bull* **21**, 829–833 (1998).
10. Kawahata, T. et al. A novel substance purified from *Perilla frutescens* Britton inhibits an early stage of HIV-1 replication without blocking viral adsorption. *Antivir Chem Chemother* **13**, 283–288 (2002).
11. Lin, C. S. et al. Growth inhibitory and apoptosis inducing effect of *Perilla frutescens* extract on human hepatoma HepG2 cells. *J Ethnopharmacol* **112**, 557–567 (2007).
12. Qin, J. et al. Subinhibitory concentrations of perilla oil affect the expression of secreted virulence factors in *Staphylococcus aureus*. *PLoS One* **6**, e16160 (2012).
13. Huang, B. P., Lin, C. H., Chen, Y. C. & Kao, S. H. Anti-inflammatory effects of *Perilla frutescens* leaf extract on lipopolysaccharide-stimulated RAW264.7 cells. *Mol Med Rep* **10**, 1077–1083 (2014).
14. Park, S. H., Shin, D., Lim, S. S., Lee, J. Y. & Kang, Y. H. Purple perilla extracts alloy ER stress in lipid-laden macrophages. *PLoS One* **9**, e105581 (2014).
15. Shin, T. Y. et al. Inhibitory effect of mast cell-mediated immediate-type allergic reactions in rats by *Perilla frutescens*. *Immunopharmacol Immunotoxicol* **22**, 489–500 (2000).
16. Kolaczkowska, E. & Kubis, P. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol* **13**, 159–175 (2013).
17. Nathan, C. Neutrophils and immunity: challenges and opportunities. *Nat Rev Immunol* **6**, 173–182 (2006).
18. Naeve, W. M. & Borregaard, N. Neutrophils at work. *Nat Immunol* **5**, 602–611 (2004).
19. Abraham, E. Neutrophils and acute lung injury. *Crit Care Med* **31**, S195–199 (2003).
20. Uriarte, S. M. et al. Inhibition of neutrophil exocytosis ameliorates acute lung injury in rats. *Shock* **39**, 286–292 (2013).
21. Hoenderdos, K. & Condiffe, A. The neutrophil in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* **48**, 531–539 (2013).
22. Ciepiela, O., Ostafin, M. & Demkow, U. Neutrophils in asthma—a review. *Respir Physiol Neurobiol* **209**, 13–16 (2015).
23. Futosi, K., Fodor, S. & Mocsai, A. Reprint of Neutrophil cell surface receptors and their intracellular signal transduction pathways. *Int Immunopharmacol* **17**, 1185–1197 (2013).
24. Fumagalli, L., Zhang, H., Baruzzi, A., Lowell, C. A. & Berton, G. The Src family kinases Hck and Fgr regulate neutrophil responses to N-formyl-methionyl-leucyl-phenylalanine. *J Immunol* **178**, 3874–3885 (2007).
25. Block, H. & Zarbock, A. The role of the tec kinase Bruton’s tyrosine kinase (Btk) in leukocyte recruitment. *Int Rev Immunol* **31**, 104–118 (2012).
26. Horwood, N., Urbaniak, A. M. & Dansky, L. Tec family kinases in inflammation and disease. *Int Rev Immunol* **31**, 87–103 (2012).
27. Schmidt, U., Boucheron, N., Unger, B. & Eilmeier, W. The role of Tec family kinases in myeloid cells. *Int Arch Allergy Immunol* **134**, 65–78 (2004).
28. Lachance, G., Levassure, S. & Naccache, P. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. Implication of phosphatidylinositol 3-kinases. *J Biol Chem* **277**, 21537–21541 (2002).
29. Gilbert, C. et al. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. Effects of LFM-A13, a specific Btk inhibitor. *J Immunol* **170**, 5235–5243 (2003).
30. Kim, C., Marchal, C. C., Pennington, J. & D'auver, M. C. The hemopoietic Rho/Rac guanine nucleotide exchange factor Vav1 regulates N-formyl-methionyl-leucyl-phenylalanine-activated neutrophil functions. *J Biol Chem* **271**, 4425–4430 (2003).
31. Price, M. O., Atkinson, S. J., Knau, U. G. & D'auver, M. C. Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent. *J Biol Chem* **277**, 19220–19228 (2002).
32. Roepstorff, K. et al. Stimulus-dependent regulation of the phagocyte NADPH oxidase by a VAV1, Rac1, and PAK1 signaling axis. *J Biol Chem* **283**, 7983–7993 (2008).
33. Turner, M. & Billadeau, D. D. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. *Nat Rev Immunol* **2**, 476–486 (2002).
34. Nijhuis, E., Lammers, J. W., Koenderman, L. & Cofer, P. J. Src kinases regulate PKB activation and modulate cytokine and chemotractant-controlled neutrophil functioning. *J Leukoc Biol* **71**, 113–124 (2002).
35. Lowell, C. A. Src-family kinases: rheostats of immune cell signaling. *Mol Immunol* **41**, 631–643 (2004).
Acknowledgements

This research was financially supported by the grants from the Ministry of Science Technology (NSC 102-2628-B-182-002-MY3), Ministry of Education (EMRPD1D1E1701), and Chang Gung Memorial Hospital (CMRPD1D0281-3, CMRPD1B0332, and CMRPG5D0121), Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

Authors C.Y.C. and T.L.H. designed the study and wrote the protocol. Author Y.L.L. carried out the extraction of Perilla frutescens. Authors Y.F., P.J.C., Y.T.K and H.W.Y. performed most experiments. Authors C.Y.C., L.M.K., W.C.S. and T.Y.F. managed the literature searches and analyses. Authors C.F.L. and M.C.L. performed the HPLC analysis. Authors C.Y.C. and T.L.H. were responsible for the overall design, analyzed data, and wrote the article.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Chen, C.-Y. et al. Anti-inflammatory effects of Perilla frutescens in activated human neutrophils through two independent pathways: Src family kinases and Calcium. Sci. Rep. 5, 18204; doi: 10.1038/srep18204 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/